; (III) information demonstrating that the weight of evidence analysis shows the substance has not been found to induce cancer when ingested by humans or animals; and (IV) information demonstrating that the weight of evidence analysis shows the substance has not been found to induce reproductive or developmental toxicity when ingested by humans or animals, including through an endocrine mode of action. (B) The revision shall require— (i) the Secretary to make each determination that is submitted pursuant to subparagraph (A)(i), and the supporting information submitted pursuant to subparagraph (A)(ii), publicly available on the website of the Food and Drug Administration; (ii) a period of at least 90 days for the Secretary and the public to review each such determination and object, if appropriate, in order to ensure that the substance involved is safe taking into account the factors listed in subparagraph (A) and in paragraphs (3) through (5) of section 409(c) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 348(c) ); and (iii) the Secretary’s objection, or decision not to object, to be considered final agency action. (C) The revision shall clarify that substances that are known (or reasonably anticipated) to cause cancer in humans or animals identified by the National Toxicology Program cannot be GRAS. (D) The revision shall clarify that substances that show clear evidence (or some evidence) of human reproductive or developmental toxicity identified by the National Toxicology Program cannot be GRAS. (E) The revision shall clarify that any substance that was not marketed for use in foods in the United States before issuance of the revised rule cannot be GRAS and shall be approved by the Secretary through a food additive petition as required by section 409(c) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 348(c) ) prior to being marketed in food. (F) The revision shall— (i) incorporate standards prohibiting conflict of interests among experts providing data for substances submitted for GRAS review